General Information of DFM (ID: F12689)
Name	Lubiprostone 0.008 mg capsule
Company	Takeda Pharmaceuticals America
Active Pharmaceutical Ingredient (API)	Lubiprostone		API Info click to show the detail info of this API
	Irritable bowel syndrome		ICD-11: DD91	Approved
Drug Inactive Ingredient (DIGs)
	DIG ID	DIG Info	DIG Name	DIG Functional Class
	E09YYN	DIG Info	Eisenoxyd	Colorant
	E04KSN	DIG Info	Hexahydric alcohol	Diluent ...
	E0X2OX	DIG Info	Medium-chain triglyceride	Emollient ...
	E05BSD	DIG Info	Titanium dioxide	Coating agent ...
	E0H2SC	DIG Info	Water	Solvent

Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM
Cell line (CELL)
DBT Name: Colon cancer Caco-2 cells (Caco-2)				Click to Show/Hide
Detailed Information	DBT Info click to show the detail info of this DBT
Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
Interacting DIG	Medium-chain triglyceride
Biological Activity	Inhibition ratio > 36 % (tested by experiment)					[1]
Tested Species	Homo sapiens (Human)

References
1	Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS). Int J Pharm. 2013 Apr 15;447(1-2):192-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.